Evidence map›Paper›PMID 42049950›Full record

ArticleNPJ precision oncology2026

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy.

Yu Fujiwara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Taylor J Jensen, Paul DePietro, R J Seager, Sadakatsu Ikeda, Razelle Kurzrock

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu Fujiwara *Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. yu.fujiwara@roswellpark.org.
Shumei Kato *Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. smkato@ucsd.edu.
Daisuke NishizakiDivision of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Hirotaka MiyashitaDivision of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Suzanna LeeDivision of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Taylor J JensenLabcorp, Durham, NC, USA.
Paul DePietroLabcorp, Durham, NC, USA.
R J SeagerLabcorp, Durham, NC, USA.
Sadakatsu IkedaDepartment of Clinical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Razelle Kurzrock *MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA. rkurzrock@mcw.edu.

Funding

NCI NIH HHS 5U01CA180888-08NCI NIH HHS NIH P30 CA023100
6 · The paper itself

Abstract

Tertiary lymphoid structures (TLSs) facilitate tumor microenvironment immune interactions. While TLSs and their associated gene signatures correlate with better response to immune checkpoint inhibitors (ICIs), the complex transcriptomic interplay/co-regulation among these factors remains under investigation. We analyzed correlations between survival and transcriptome expression (35 immunoregulatory factors associated with B/T cells and TLSs) in 217 patients with ICI-treated solid tumors. Denser correlations among B/T cell markers, immune checkpoints, and TLS-related molecules was associated with longer survival. High CXCL13 (B-lymphocyte chemoattractant) expression correlated with longer overall survival (hazard ratio [HR] 0.46 [95% CI: 0.27-0.81], p = 0.006) in 217 ICI-treated patients but not in 272 ICI-naïve patients (HR 0.85 [0.52-1.40], p = 0.519), suggesting its potential predictive/ICI-related, rather than prognostic, value. Overall, patients with highly coordinated T- and B-cell activity, checkpoints, and TLS-related molecules, and higher CXCL13 expression demonstrated prolonged survival after ICIs. Comprehensive multiomics and tumor immunomic profiling may better predict outcome after immunotherapy.

Identifiers

PMID42049950
PMCPMC13328500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.